DOCSLIB.ORG

Medicine Price List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicine Price List Highest possible Name Packaging Ingredient Permit holder Rep retail price inlcuding VAT C944009/1 ABASAGLAR SOLUTION FOR INJECTION 100U/ML 10 CARTRIDGES X 3ML INSULIN GLARGINE ELI LILLY REGIONAL OPERATIONS GMBH PHADISCO LTD 100.45 9600152/1 ABELCET SUSPENSION FOR INJECTION 100MG/20ML 10 VIALS AMPHOTERICIN B TEVA PHARMACEUTICALS LTD C.A. PAPAELLINAS & CO LTD 1301.84 2500177/1 ABERNIL TABLET 50MG 50 TABS NALTREXONE MEDOCHEMIE LTD MEDOCHEMIE LTD 69.86 C882002/1 ABILIFY MAINTENA POWDER & SOLVENT FOR PROLONGED RELEASE SUSPENION FOR INJECTION 400MG/VIAL PACK WITH 1 VIAL WITH SOLVENT ARIPIPRAZOLE OTSUKA PHARMACEUTICAL EUROPE LTD C G PAPALOISOU LTD 366.82 C276034/1 ABILIFY ORAL SOLUTION 1MG/ML 1 BOTTLEX150 ML ARIPIPRAZOLE OTSUKA PHARMACEUTICAL EUROPE LTD M S JACOVIDES & CO LTD 138.08 C276036/1 ABILIFY SOLUTION FOR INJECTION 7.5MG/ML 1 VIAL X1.3ML ARIPIPRAZOLE OTSUKA PHARMACEUTICAL EUROPE LTD C G PAPALOISOU LTD 6.80 C04276A/1 ABILIFY TABLET 10MG 28 TABS ARIPIPRAZOLE OTSUKA PHARMACEUTICAL EUROPE LTD M S JACOVIDES & CO LTD 78.59 C04276B/1 ABILIFY TABLET 15MG 28 TABS ARIPIPRAZOLE OTSUKA PHARMACEUTICAL EUROPE LTD M S JACOVIDES & CO LTD 77.14 C276017/1 ABILIFY TABLET 30MG 28 TABS ARIPIPRAZOLE OTSUKA PHARMACEUTICAL EUROPE LTD M S JACOVIDES & CO LTD 160.64 C428001/1 ABRAXANE POWDER FOR SUSPENSION FOR INFUSION 5MG/ML 1 VIAL (100MG) PACLITAXEL CELGENE EUROPE LTD GENESIS PHARMA (CYPRUS) LTD 348.51 C412016/1 ABSEAMED SOLUTION FOR INJECTION 10000IU/1ML 6 PRE-FILLED SYRINGES EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 459.23 C412004/1 ABSEAMED SOLUTION FOR INJECTION 2000IU/1ML 6 PRE-FILLED SYRINGES EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 106.10 C412006/1 ABSEAMED SOLUTION FOR INJECTION 3000IU/0.3ML 6 PRE-FILLED SYRINGES EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 159.33 C412025/1 ABSEAMED SOLUTION FOR INJECTION 40000IU/1ML 1 PRE-FILLED SYRINGE EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 316.58 C412026/1 ABSEAMED SOLUTION FOR INJECTION 40000IU/1ML 6 PRE-FILLED SYRINGE EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 1785.17 C412008/1 ABSEAMED SOLUTION FOR INJECTION 4000IU/0.4ML 6 PRE-FILLED SYRINGES EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 216.09 C412010/1 ABSEAMED SOLUTION FOR INJECTION 5000IU/0.5ML 6 PRE-FILLED SYRINGES EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 266.24 C412012/1 ABSEAMED SOLUTION FOR INJECTION 6000IU/0.6ML 6 PRE-FILLED SYRINGES EPOETIN ALFA MEDICE ARZNEIMITTEL PUTTER GMBH & CO KG PAPAETIS MEDICAL CO LTD 324.61 ABSTRAL TABLET, SUBLINGUAL 100MCG 30 TABS FENTANYL PROSTRAKAN LTD C.A. PAPAELLINAS & CO LTD 255.77 ABSTRAL TABLET, SUBLINGUAL 200MCG 30 TABS FENTANYL PROSTRAKAN LTD C.A. PAPAELLINAS & CO LTD 255.77 ABSTRAL TABLET, SUBLINGUAL 300MCG 30 TABS FENTANYL PROSTRAKAN LTD C.A. PAPAELLINAS & CO LTD 255.77 26M0116/1 ABSTRAL TABLET, SUBLINGUAL 400MCG 30 TABS FENTANYL PROSTRAKAN LTD C.A. PAPAELLINAS & CO LTD 255.77 26M0117/1 ABSTRAL TABLET, SUBLINGUAL 600MCG 30 TABS FENTANYL PROSTRAKAN LTD C.A. PAPAELLINAS & CO LTD 256.07 26M0118/1 ABSTRAL TABLET, SUBLINGUAL 800MCG 30 TABS FENTANYL PROSTRAKAN LTD C.A. PAPAELLINAS & CO LTD 256.07 2600191/4 ACAPRIL 10 TABLET 10MG 30 TABS RAMIPRIL REMEDICA LTD REMEDICA LTD 14.03 2600189/4 ACAPRIL 2.5 TABLET 2.5MG 30 TABS RAMIPRIL REMEDICA LTD REMEDICA LTD 9.36 2600190/4 ACAPRIL 5 TABLET 5MG 30 TABS RAMIPRIL REMEDICA LTD REMEDICA LTD 11.73 9900615/1 ACARILBIAL LIQUID 277MG/ML 200 ML BENZYL BENZOATE BIAL-PORTELA & CA, SA GEORGE PETROU LTD 6.33 9000392/1 ACCUPRON TABLET, FILM COATED 20MG 28 TABS QUINAPRIL PFIZER HELLAS AE GEO PAVLIDES & ARAOUZOS PHARMACEUTICALS LTD 12.94 9000391/1 ACCUPRON TABLET, FILM COATED 5MG 28 TABS QUINAPRIL PFIZER HELLAS AE GEO PAVLIDES & ARAOUZOS PHARMACEUTICALS LTD 7.81 31S0075/1 ACECLONAC TABLET, FILM COATED 100MG 40 TABS ACECLOFENAC VERISFIELD (UK) LTD C.A. PAPAELLINAS & CO LTD 8.60 2300028/1 ACEPROTIN TABLET 25MG 20 TABS CAPTOPRIL CODAL SYNTO LTD CODAL SYNTO LTD 5.55 2300029/1 ACEPROTIN TABLET 50MG 20 TABS CAPTOPRIL CODAL SYNTO LTD CODAL SYNTO LTD 8.23 8300223/1 ACETAZOLAMIDE TABLET 250MG 30 TABS ACETAZOLAMIDE REMEDICA LTD REMEDICA LTD 4.54 26S0021/1 ACETYLCYSTEINE SOLUTION FOR INFUSION 20% W/V 10 X10ML ACETYLCYSTEINE AURUM PHARMACEUTICALS LTD MEDILINK PHARMACEUTICALS LTD 33.53 9700326/1 ACIC CREAM 5% 5 G TUBE ACICLOVIR HEXAL AG P.T.HADJIGEORGIOU CO LTD 7.05 26S0262/1 ACICLOVIR MYLAN POWDER FOR SOLUTION FOR INJECTION 250MG/VIAL 5 VIALS ACICLOVIR MYLAN SAS PHARMACEUTICAL TRADING CO LTD 14.39 27S0045/1 ACICLOVIR ORAL SUSPENSION 200MG/5ML 125 ML ACICLOVIR ROSEMONT PHARMACEUTICALS LTD MEDILINK PHARMACEUTICALS LTD 29.81 C05308A/1 ACLASTA SOLUTION FOR INJECTION 5MG/100ML 100 ML ZOLEDRONIC ACID NOVARTIS EUROPHARM LIMITED UK NOVARTIS PHARMA SERVICES INC., CYPRUS 333.69 CLINDAMYCIN PHOSPHATE, 31M0103/1 ACNATAC GEL 1 TUBE OF 30G MEDA PHARMACEUTICALS SA C G PAPALOISOU LTD 26.57 TRETINOIN 1 VIAL WITH PRE-FILLED SYRINGE X VACCINE (HEMOPHILUS 9300288/1 ACT-HIB POWDER AND SOLVENT FOR SOLUTION FOR INJECTION SANOFI PASTEUR SA G A STAMATIS & CO LTD 25.92 0.5ML INFLUENZAE TYPE B) COUGH AND COLD PREPARATIONS 8400119/1 ACTIFED DM COUGH LINCTUS SYRUP 100 ML (DEXTROMETHORPHAN, GLAXO GROUP LTD KAPAKIOTIS & PAPAELLINAS LTD 5.01 PSEUDOEPHEDRINE, TRIPROLIDINE) COUGH AND COLD PREPARATIONS 2300009/1 ACTIFED EXPECTORANT ORAL SOLUTION 200 ML (GUAIFENESIN, GLAXO GROUP LTD KAPAKIOTIS & PAPAELLINAS LTD 7.25 PSEUDOEPHEDRINE, TRIPROLIDINE) COUGH AND COLD PREPARATIONS 2200175/1 ACTIFED SYRUP 200 ML GLAXO GROUP LTD KAPAKIOTIS & PAPAELLINAS LTD 7.00 (PSEUDOEPHEDRINE, TRIPROLIDINE) PACK WITH 5 VIALS WITH 5 AMPS X 34S0044/1 ACTILYSE CATHFLO POWDER AND SOLVENT FOR SOLUTION FOR INFUSION/INJECTION 2MG/VIAL ALTEPLASE BOEHRINGER INGELHEIM ELLAS AE CYPRUS PHARMACEUTICAL ORGANIZATION LTD 282.04 2.2ML 8800298/2 ACTILYSE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 50MG/VIAL 2 x50MG KIT(S) ALTEPLASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH,GERMANY CYPRUS PHARMACEUTICAL ORGANIZATION LTD 1200.61 8800298/1 ACTILYSE POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 50MG/VIAL 1 SET (VIAL + 50ML SOLVENT) ALTEPLASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH,GERMANY CYPRUS PHARMACEUTICAL ORGANIZATION LTD 600.32 26M0153/1 ACTONEL (2 CONSEQUENTIAL DAYS PER MONTH) TABLET, FILM COATED 75MG 2 TABS RISEDRONATE ACTAVIS GROUP PTC EHF A POTAMITIS MEDICARE LTD 23.84 25M0021/3 ACTONEL OAW TABLET, FILM COATED 35MG 4 TABS RISEDRONATE ACTAVIS GROUP PTC EHF A POTAMITIS MEDICARE LTD 15.62 ANTACIDS (ALUMINIUM, 7800299/1 ACTONORM GEL ORAL SUSPENSION 200 ML PHARMACEUTICAL TRADING CO LTD PHARMACEUTICAL TRADING CO LTD 5.51 MAGNESIUM), SIMETICONE Σελ. 1 από 108 Highest possible Name Packaging Ingredient Permit holder Rep retail price inlcuding VAT ANTACIDS, ATROPINE IN 9500332/1 ACTONORM ORAL POWDER 85 G PHARMACEUTICAL TRADING CO LTD PHARMACEUTICAL TRADING CO LTD 4.69 COMBINATION C02230B/1 ACTRAPID PENFILL SOLUTION FOR INJECTION 100IU/ML 5 X3ML CARTRIDGES INSULIN SOLUBLE NOVO NORDISK A/S VARNAVAS HADJIPANAYIS LTD 33.31 C02230A/1 ACTRAPID SOLUTION FOR INJECTION 100IU/ML 1VIAL X 10ML INSULIN SOLUBLE NOVO NORDISK A/S VARNAVAS HADJIPANAYIS LTD 15.71 VACCINE (DIPHTERIA, 29M0221/1 ADACEL SUSPENSION FOR INJECTION 1 VIAL X 0.5ML SANOFI PASTEUR SA G A STAMATIS & CO LTD 20.34 TETANUS, PERTUSSIS) 9900222/1 ADAFERIN GEL 0.1% 30 G ADAPALENE GALDERMA INTERNATIONAL,FRANCE C G PAPALOISOU LTD 7.78 2000367/2 ADALAT CR TABLET 30MG 28 TABS NIFEDIPINE BAYER HELLAS ABEE NOVAGEM LTD 12.59 2000368/2 ADALAT CR TABLET 60MG 28 TABS NIFEDIPINE BAYER HELLAS ABEE NOVAGEM LTD 14.35 ELECTROLYTES IN COMB 29S0125/1 ADDAMEL N SOLUTION FOR INFUSION 20 AMPS X 10ML FRESENIUS KABI HELLAS AE INNOPRO MEDICAL SERVICES LTD 41.20 WITH OTHER DRUGS BUPRENORPHINE 31M0069/18 ADDICTEX TABLET, SUBLINGUAL 0.4MG 7 TABLET ACTAVIS GROUP PTC EHF A POTAMITIS MEDICARE LTD 2.36 HYDROCHLORIDE BUPRENORPHINE 30M0254/9 ADDICTEX TABLET, SUBLINGUAL 2MG 7 TABLET ACTAVIS GROUP PTC EHF A POTAMITIS MEDICARE LTD 6.41 HYDROCHLORIDE BUPRENORPHINE 30M0255/9 ADDICTEX TABLET, SUBLINGUAL 8MG 7 TABLET ACTAVIS GROUP PTC EHF A POTAMITIS MEDICARE LTD 10.90 HYDROCHLORIDE C907001/1 ADEMPAS TABLET, FILM COATED 0.5MG 42 TABS RIOCIGUAT BAYER PHARMA AG MERCK SHARP AND DOHME CYPRUS LTD 1589.22 C907007/1 ADEMPAS TABLET, FILM COATED 1.5MG 42 TABS RIOCIGUAT BAYER PHARMA AG MERCK SHARP AND DOHME CYPRUS LTD 1589.22 C907004/1 ADEMPAS TABLET, FILM COATED 1MG 42 TABS RIOCIGUAT BAYER PHARMA AG MERCK SHARP AND DOHME CYPRUS LTD 1589.22 C907013/1 ADEMPAS TABLET, FILM COATED 2.5MG 42 TABS RIOCIGUAT BAYER PHARMA AG MERCK SHARP AND DOHME CYPRUS LTD 1589.22 C907010/1 ADEMPAS TABLET, FILM COATED 2MG 42 TABS RIOCIGUAT BAYER PHARMA AG MERCK SHARP AND DOHME CYPRUS LTD 1589.22 9600520/2 ADENOSAN SHAMPOO 2% W/W 180 ML KETOCONAZOLE IASIS PHARMACEUTICALS HELLAS SA LOUANFARM TRADING CO LTD 9.94 32S0009/1 ADENOSINE SOLUTION FOR INJECTION 3MG/ML 6 VIALS X 2ML VIALS ADENOSINE WOCKHARDT UK LTD MEDILINK PHARMACEUTICALS LTD 29.95 C447003/1 ADENURIC TABLET, FILM COATED 120MG 28 TABS FEBUXOSTAT MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA KYPROPHARM LTD 36.11 C447001/1 ADENURIC TABLET, FILM COATED 80MG 28 TABS FEBUXOSTAT MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA KYPROPHARM LTD 34.61 ADELCO-CHROMATOURGIA ATHINON E.COLOCOTRONIS 31S0052/1 ADEPRENAL ORAL DROPS SOLUTION 40MG/ML 15 ML CITALOPRAM COSTAKIS TSISIOS & CO LTD 12.84 BROS S.A 2500012/1 ADIZEM-XL PROLONGED RELEASE CAPSULES 120MG 20 CAPS DILTIAZEM MUNDIPHARMA PHARMACEUTICALS LTD MUNDIPHARMA PHARMACEUTICALS LTD 12.12 2500013/1 ADIZEM-XL PROLONGED RELEASE CAPSULES 180MG 20 CAPS DILTIAZEM MUNDIPHARMA PHARMACEUTICALS LTD MUNDIPHARMA PHARMACEUTICALS LTD 12.12 2500014/1 ADIZEM-XL PROLONGED RELEASE CAPSULES 240MG 20 CAPS DILTIAZEM MUNDIPHARMA PHARMACEUTICALS LTD MUNDIPHARMA PHARMACEUTICALS LTD 12.64 2300194/1 ADRENALINE INJECTION 1MG/ML 50 AMP X1ML EPINEPHRINE THE STAR MEDICINES IMPORTERS & CO LTD THE STAR MEDICINES IMPORTERS & CO LTD 66.90 26S0288/1 ADRENALINE SOLUTION FOR INJECTION 0.01%W/V 1 Χ10ML PRE-FILLED SYR.
Load more

Recommended publications
  • Sl Generic Name Brand Name Originator Brand Dosage Form
    www.beaconpharma.com.bd Beacon Business Center, [email protected] 9/B/2,Toyenbee Circular Beacon Pharmaceuticals Limited Road,Motijheel,Dhaka. Product List ONCOLOGY Anti-Cancer Parenterals Originator Sl Generic Name Brand Name Dosage Form Strength Pack Size Brand 1 Bendamustine Bendamax Treanda Injection 25 mg 1's Vial 2 Bortezomib Bortez injection velcade injection 1 mg 1's Vial 3 Bleomycin Sulfate Bleonix Blenoxane Injection 15000 IU 1's vial 4 Calcium folinate Folinex Leucovorin Injection 50 gm 1's Vial 5 Carboplatin Carboplat 150 Paraplatin Injection 150 mg 1’s Vial Carboplat 450 450 mg 6 Cisplatin Platinex 10 Platinol Injection 10 mg 1’s Vial 7 Cyclophosphamide PlatinexCyclotox 50 Cytoxan Injection 501 mgg 1’s Vial Cyclotox 200 200 mg Cytabin 100 100 mg 8 Cytarabine Cytabin500 Cytosar-U Injection 500 mg 1's Vial Cytabin 1000 1g 9 Dacarbazine Dacarzin DTIC Injection 200 mg 1's Vial 10 Daunorubicin Rubicin Daunomucin Injection 20 mg 1's Vial Injection 1’s Vial 11 Docetaxel Docexan 20 Taxotere 20 mg Docexan 80 Injection 80 mg 1’s Vial Injection 1’s Vial 12 Doxorubicin Xorubin 10 Adriamycin 10 mg Xorubin 50 Injection 50 mg 1’s Vial 1x7's Vial 13 Epirubicin Erubin 10 Ellence Injection 10 mg Erubin 50 50 mg 1's Vial 14 Etoposide Topoxin VePesid Injection 100 mg 1’s Vial 15 Fluorouracil Fluroxan 250 Adrucil Injection 250 mg 1’s Vial Fluroxan 500 500 mg 1x2's Vial 16 Gemcitabine Gemoxen 200 Gemzar Injection 200 mg Gemoxen 1 g 1's Vial 17 Ifosphamide Xifos 1 Ifex Injection 1 g 1's Vial Xifos 2 2 g 3x10's Vial 18 Irinotecan Irinox 40
    [Show full text]
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • Freedom of Information Act Request – Reference Foi/13/116 New Drugs Added to Formulary
    Freedom of Information Act Request – Reference FoI/13/116 New Drugs Added to Formulary Request details Please will you provide me with numbers of new drugs that your LHB has introduced over the past three years, listing the number of new drugs introduced by year in each of those years? Response 2010 = 41 2011 = 53 2012 = 71 2010 Generic Name 1. adalimumab, etanercept, infliximab, rituximab and abatacept 2. beclometasone and formoterol (Fostair®) 3. bortezomib (Velcade®) in combination with melphalan and prednisone 4. Brinzolamide/timolol (Azarga®) 5. bromocriptine 6. calcium and vitamin D3 (Calceos®) 7. calcium and vitamin D (Adcal D3 Dissolve®) 8. capecitabine 9. Carmellose eye drops (Optive®) 10. Certolizumab pegol 11. Darunavir (Prezista®▼) 12. epoetin alfa (Binocrit®) 13. epoetin theta (Eporatio®) 14. Eslicarbazepine acetate (Zebinix®) 15. Evicel 16. fentanyl buccal tablets (Effentora) 17. fentanyl intranasal spray (Instanyl®) 18. Fesoterodine (Toviaz®) 19. filgrastim (TevaGrastim®) 20. filgrastim (Zarzio®) 21. gefitinib 22. infliximab and adalimumab 23. liraglutide (Victoza®) 24. Loperamide tablets 25. losartan 26. Mepilex® Ag 27. Movicol Paediatric 28. Nebuchamber 29. paclitaxel albumin (Abraxane®) monotherapy 30. pemetrexed 31. Plerixafor (Mozobil®q) 32. pramipexole prolonged release (Mirapexin®) 33. Prontosan® wound irrigation solution and gel 34. quinagolide (Norprolac®) 35. raltegravir (Isentress®) 36. rituximab sildenafil (Revatio®) tablets 2010 Generic Name 37. sodium chloride (7%) Nebusal® 38. somatropin (NutropinAq®) 39. Topotecan 40. Trabectedin 41. Xamiol 2011 Generic Name 1. artemether and lumefantrine (Riamet®) 2. artesunate 3. atazanavir (Reyataz®) co-administered with low dose ritonavir 4. azacitidine 5. aztreonam (Azactam®) 6. bendamustine 7. Bivalirudin 8. Bortezomib 9. Calcium acetate and magnesium carbonate (Osvaren®) 10. darunavir (Prezista®) 11.
    [Show full text]
  • (Epoetin and Darbepoetin) for Treating Cancer Treatment-Induced Anaemia (Including Review of Technology Appraisal No
    HEALTH TECHNOLOGY ASSESSMENT VOLUME 20 ISSUE 13 FEBRUARY 2016 ISSN 1366-5278 The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model Louise Crathorne, Nicola Huxley, Marcela Haasova, Tristan Snowsill, Tracey Jones-Hughes, Martin Hoyle, Simon Briscoe, Helen Coelho, Linda Long, Antonieta Medina-Lara, Ruben Mujica-Mota, Mark Napier and Chris Hyde DOI 10.3310/hta20130 The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model Louise Crathorne,1* Nicola Huxley,1 Marcela Haasova,1 Tristan Snowsill,1 Tracey Jones-Hughes,1 Martin Hoyle,1 Simon Briscoe,1 Helen Coelho,1 Linda Long,1 Antonieta Medina-Lara,2 Ruben Mujica-Mota,1 Mark Napier3 and Chris Hyde1 1Peninsula Technology Assessment Group (PenTAG), University of Exeter Medical School, Exeter, UK 2University of Exeter Medical School, Exeter, UK 3Royal Devon and Exeter Hospital, Exeter, UK *Corresponding author Declared competing interests of authors: none Published February 2016 DOI: 10.3310/hta20130 This report should be referenced as follows: Crathorne L, Huxley N, Haasova M, Snowsill T, Jones-Hughes T, Hoyle M, et al. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model. Health Technol Assess 2016;20(13). Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/ Clinical Medicine.
    [Show full text]
  • List of Patented Medicines 2018
    Patented Medicine Annual Report List 02 Apr 2019 Prices Review Board Protected A DIN Brand Chemical Name ATC Dosage Comments Status ABBVIE 02436027 HOLKIRA PAK 12.5/75/50/250 ombitasvir/paritaprevir/ritonavir/dasabuvir J05AX Oral Solid /Tablet Within Guidelines 02258595 HUMIRA - 40 MG/SYRINGE adalimumab L04AA Parenteral /Solution Within Guidelines 02312301 KALETRA 100/25 MG/TABLET lopinavir/ritonavir J05AE Oral Solid /Tablet Within Guidelines 02285533 KALETRA 200/50 MG/TABLET lopinavir/ritonavir J05AE Oral Solid /Tablet Within Guidelines 02243644 KALETRA 80/20 MG/MILLILITER lopinavir/ritonavir J05AE Oral Liquid /Solution Does Not Trigger 00884502 LUPRON DEPOT - 3.75 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 00836273 LUPRON DEPOT - 7.5 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02239834 LUPRON DEPOT - 11.25 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02230248 LUPRON DEPOT - 22.5 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02239833 LUPRON DEPOT - 30 MG/VIAL leuprolide acetate L02AE Parenteral /Modified release injections Within Guidelines 02467550 MAVIRET 100/40 MG/TABLET glecaprevir/pibrentasvir J05AP Oral Solid /Tablet Subj. Investigation 02229145 NORVIR - 80 MG/MILLILITER ritonavir J05AE Oral Liquid /Solution Within Guidelines 02357593 NORVIR - 100 MG/TABLET ritonavir J05AE Oral Solid /Tablet Within Guidelines 02481332 ORILISSA - 150 MG/TABLET elagolix
    [Show full text]
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K
    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]
  • Biosimilar Epoetins and Other ``Follow-On
    Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences Wolfgang Jelkmann To cite this version: Wolfgang Jelkmann. Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences. American Journal of Hematology, Wiley, 2010, 85 (10), pp.771. 10.1002/ajh.21805. hal-00552331 HAL Id: hal-00552331 https://hal.archives-ouvertes.fr/hal-00552331 Submitted on 6 Jan 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. American Journal of Hematology Biosimilar epoetins and other “follow-on” biologics: Update on the European experiences For Peer Review Journal: American Journal of Hematology Manuscript ID: AJH-10-0229.R1 Wiley - Manuscript type: Critical Review Date Submitted by the 10-Jun-2010 Author: Complete List of Authors: Jelkmann, Wolfgang; University, Physiology Anemias, Erythropoietin, Hematology- medical, Neutropenia, Keywords: Pharmacology John Wiley & Sons Page 1 of 30 American Journal of Hematology 1 2 3 Table II. Benefits and problems related to the use of biosimilars 4 5 ________________________________________________________________ 6 Benefits Problems 7 ______________________________________________________________________ 8 9 10 Lower pricing than originator medicines Lack of long-term experience 11 (efficacy, safety, immunogenicity?) 12 13 Pressure on innovator companies Product-specific administration routes 14 15 to reduce prices of originator medicines (s.c.
    [Show full text]
  • Beacon Pharmaceuticals Limited Road,Motijheel,Dhaka
    www.beaconpharma.com.bd Beacon Business Center, [email protected] 9/B/2,Toyenbee Circular Beacon Pharmaceuticals Limited Road,Motijheel,Dhaka. Product List ONCOLOGY Anti-Cancer Parenterals Originator Sl Generic Name Brand Name Dosage Form Strength Pack Size Brand 1 Bendamustine Bendamax Treanda Injection 25 mg 1's Vial Bortez 1 mg 1's Vial 2 Bortezomib Velcade injection Bortez 2 2 mg 1's Vial 3 Bleomycin Sulfate Bleonix Blenoxane Injection 15000 IU 1's vial 4 Calcium folinate Folinex Leucovorin Injection 50 gm 1's Vial Carboplat 150 150 mg 5 Carboplatin Paraplatin Injection 1’s Vial Carboplat 450 450 mg Platinex 10 10 mg 6 Cisplatin Platinol Injection 1’s Vial Platinex 50 50 mg Cyclotox 1 g 7 Cyclophosphamide Cytoxan Injection 1’s Vial Cyclotox 200 200 mg Cytabin 100 100 mg 8 Cytarabine Cytabin500 Cytosar-U Injection 500 mg 1's Vial Cytabin 1000 1 g 9 Dacarbazine Dacarzin DTIC Injection 200 mg 1's Vial 10 Daunorubicin Rubicin Daunomucin Injection 20 mg 1's Vial Docexan 20 Injection 20 mg 1’s Vial 11 Docetaxel Taxotere Docexan 80 Injection 80 mg 1’s Vial Xorubin 10 Injection 10 mg 1’s Vial 12 Doxorubicin Adriamycin Xorubin 50 Injection 50 mg 1’s Vial Erubin 10 10 mg 13 Epirubicin Ellence Injection 1's Vial Erubin 50 50 mg 14 Etoposide Topoxin VePesid Injection 100 mg 1’s Vial Fluroxan 250 250 mg 15 Fluorouracil Adrucil Injection 1’s Vial Fluroxan 500 500 mg Gemoxen 200 200 mg 16 Gemcitabine Gemzar Injection 1’s Vial Gemoxen 1 g Xifos 1 1 g 17 Ifosphamide Ifex Injection 1's Vial Xifos 2 2 g Irinox 40 40 mg 18 Irinotecan Campto Injection
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Department of Health
    DEPARTMENT OF HEALTH National Drug Policy - Pharmaceutical Management Unit 50 National Formulary Committee Philippine National Drug Formulary EssentialEssential MedicinesMedicines ListList Volume I, 7th Edition ( 2008 ) Published by: The National Formulary Committee National Drug Policy ‐ Pharmaceutical Management Unit 50 DEPARTMENT OF HEALTH Manila, Philippines All rights reserved 2008 The National Formulary Committee National Drug Policy‐Pharmaceutical Management Unit 50 (NDP‐PMU 50) Department of Health San Lazaro Cmpd., Rizal Ave., Sta. Cruz, Manila, Philippines 1003 ISBN 978‐971‐91620‐7‐0 Any part or the whole book may be reproduced or transmitted without any alteration, in any form or by any means, with permission from DOH provided it is not sold commercially. ii PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 NATIONAL FORMULARY COMMITTEE Estrella B. Paje-Villar, MD, DTM & H Chairperson Jose M. Acuin, MD, MSc Alma L. Jimenez, MD Alejandro C. Baroque II, MD Marieta B. de Luna, MD Bu C. Castro, MD Nelia P. Cortes-Maramba, MD Dina V. Diaz, MD Yolanda R. Robles, PhD Pharm Mario R. Festin, MD, MS, MHPEd Isidro C. Sia, MD BFAD Representative SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta.
    [Show full text]